Age at time of treatment: 18 – 25
Injury Level: C7
Treatment Received: Stem Cells, Epidural Stimulation
Location of Treatment: Thailand
Time between injury and treatment: —
Date of Surgery: 02/09/2018
Date of Discharge: 05/10/2018
Patient sustained a C7 fracture-dislocation on November 2, 2016. He experienced subsequent spinal cord myelomalacia (softening of the spinal cord) and has minimal motor or sensory function below the injury level. He has neurogenic bowel and bladder. Patient does not suffer severe spasticity but does suffer moderate to severe neuropathic pain, particularly in the upper extremities. This is managed by high doses of Gabapentin (600 mg, 4 times a day). Patient is able to move his upper limbs and is independent in his daily activities.
Prior to coming to Verita Neuro, patient received stem cell treatment in 2017, as well as physical and occupational therapy.
Patient sustained a C7 fracture-dislocation on November 2, 2016. He experienced subsequent spinal cord myelomalacia (softening of the spinal cord) and has minimal motor or sensory function below the injury level. He has neurogenic bowel and bladder. Patient does not suffer severe spasticity but does suffer moderate to severe neuropathic pain, particularly in the upper extremities. This is managed by high doses of Gabapentin (600 mg, 4 times a day). Patient is able to move his upper limbs and is independent in his daily activities.
After a spinal MRI scan and comprehensive blood work, patient underwent laminectomy and implantation of the epidural stimulation device. The device is the ‘Medtronic Restore Advance 16-electrode MRI Compatible Device’. The surgery was completed without significant adverse effects and the surgical wound healed normally. No serious complications were reported during the hospital stay. Patient also received 100 million Amniotic Fluid Stem Cells (hAFSC) through a combination of IV injection and lumbar puncture injection. Device Mapping and physical therapy were carried out after surgery for 35 days, and the patient was discharged.
Improvements are monitored in 15 targeted areas: 11 Motor areas and 4 Sensory areas. However, the number of targeted areas may vary depending on patient’s condition prior to admission. If patient does not experience symptoms in certain Motor/Sensory functions, or is not impaired in a specific targeted area prior to surgery, it is excluded from the report (Not Applicable). If there is progress in any given area — either mild, moderate, or significant — it is measured and reported as positive (“Yes”). No improvement, the existence of pain or spasms, or an inability to perform a measured function is reported as “No”.
In this patient, fine motor skills were normal, therefore 14 areas instead of 15 were targeted. Motor function improved in 10 out of 10 targeted areas when the Epidural Stimulation device was switched on. There was no change in neuropathic pain. Patient has not noticed any changes in Sensory Function areas, and more feedback will be collected after 3 months to note any improvements made by regenerative medicine treatment. Overall, improvements were recorded in 10 out of 14 targeted Motor and Sensory Function areas.
epiduralstimulationnow.com is owned by Verita Neuro Pte. Ltd. Verita Neuro provides access to progressive, responsible healthcare to increase the quality of life. Verita Neuro partners with leading-edge, next-generation treatment providers, unique products and services, that are integrative, safe and effective. Verita Neuro is not a treatment provider.
All medical treatments have varied outcomes. Results from the treatments will vary from patient to patient. All examples of what has been achieved by others should not be taken as typical or in any way a guarantee or projection of what any individual can expect from treatment.